June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Intravitreal Autologous Bone Marrow Derived Cells in Stargardt disease patients: Results after 3 months follow-up
Author Affiliations & Notes
  • Luiza Toscano
    Ophthalmology, USP HC RP, Ribeirão Preto, Brazil
  • Carina Costa Cotrim
    Ophthalmology, USP HC RP, Ribeirão Preto, Brazil
  • Rodrigo Jorge
    Ophthalmology, USP HC RP, Ribeirão Preto, Brazil
  • Andre Messias
    Ophthalmology, USP HC RP, Ribeirão Preto, Brazil
  • Rubens C Siqueira
    Ophthalmology, USP HC RP, Ribeirão Preto, Brazil
  • Footnotes
    Commercial Relationships Luiza Toscano, None; Carina Costa Cotrim, None; Rodrigo Jorge, None; Andre Messias, None; Rubens Siqueira, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3828. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Luiza Toscano, Carina Costa Cotrim, Rodrigo Jorge, Andre Messias, Rubens C Siqueira; Intravitreal Autologous Bone Marrow Derived Cells in Stargardt disease patients: Results after 3 months follow-up. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3828. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To evaluate the effects of a single intravitreal injection of autologous bone marrow derived mononuclear cells containing CD 34+ cells<br /> (ABMSC) in patients with Stargardt macular distrophy.

 
Methods
 

A prospective, single blind, nonrandomized clinical trial, including 9 Stargardt patients able to perform reliable visual field examination (single, and relatively stable fixation locus). Intravitreal ABMSC injection was performed in the eye with worst visual acuity - study eye (SE), while the contralateral eye served as control (CE). Evaluations included best-corrected visual acuity (BCVA), fluorescein angiography (FA), fundus autofluorescence (AF), microperimetry (MAIA - CenterVue) for fixation stability (BCEA), and macular sensitivity (AVTH) determination. Multifocal electroretinograms (ERG) were performed according to the ISCEV standard using Espion E2 (Diagnosys LLC). Examinations were performed at baseline, 1, 3, 8 and 12 months after injection.

 
Results
 

Six patients finished 3 months follow-up, and none showed significant adverse effects. At baseline,mean±SE BCVA was SE:1.04±0.08logMAR, and CE:0.98±0.08logMAR. A slightly higher BCVA improvement was observed at 1 month for SE:0.11±0.05 logMAR than for CE:0.4±0.04 logMAR (P=0.0196), and at 3 months SE:0.15±0.05 logMA; CE:0.05±0.05 logMAR (P=0.0098). AVTH at baseline was SE:15.47±1.93 dB and CE:17.13 ± 1.95 dB, and although a small but significant improvement of 3.99±1.33 dB (P=0.0086) and 5.93±2.02 dB (P=0.0133) was observed for SE at 1 and 3 months respectively, this change was not statistically significant different (P>0.05) to the variation observed for CE: 1.84±1.84 dB (P=0.1728) and 3.56±3.05 dB (P=0.1563) at 1 and 3 months respectively. No significant changes were observed for BCEA,mfERG responses amplitudes and latencies or macular structure assessed with OCT and FA or AF.

 
Conclusions
 

These data indicate that intravitreal ABMSC is associated to a small improvement of visual acuity and macular sensitivity thresholds up to 3 months after injection in Stargardt disease. Longer follow-up and a large number of cases are needed to confirm these findings.  

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×